Voglibose tablets 0.3 mg for postprandial hyperglycemia (Voglib, Volix)
What are Voglibose tablets 0.3 mg for postprandial hyperglycemia (Voglib, Volix)?
Voglibose operates as an alpha-glucosidase inhibitor, exerting its therapeutic influence through a sophisticated mechanism of action. This medication effectively hinders the activity of digestive enzymes responsible for breaking down complex carbohydrates into simpler sugars. By doing so, Voglibose provokes a slowdown in the digestion and absorption of these sugars in the gastrointestinal tract.
This intricate process unfolds as Voglibose impedes the enzymatic breakdown of carbohydrates, preventing the rapid conversion of starches and disaccharides into glucose molecules. Consequently, this delayed digestion and absorption lead to a more gradual release of glucose into the bloodstream. By retarding the post-meal surge in blood glucose levels, Voglibose tablets play a crucial role in glycemic control.
Voglibose tablets are renowned for their efficacy in mitigating the sharp spikes in blood sugar levels that often occur after meals. They are commonly employed in the management of both insulin-dependent diabetes mellitus and non-insulin-dependent diabetes mellitus, making them a versatile tool in diabetes care. Importantly, Voglibose's impact on blood glucose is particularly notable in the postprandial phase, which is pivotal for overall glycemic control.
Moreover, the safety profile of Voglibose tablets is well-established, with minimal reported side effects, rendering them a reliable option for diabetes management. Clinical research has not only confirmed their safety but has also indicated their potential in preventing the onset of diabetes in individuals with impaired glucose tolerance. This preventive aspect underscores the multifaceted utility of Voglibose in addressing various facets of diabetes care, ranging from acute post-meal glucose regulation to long-term diabetes prevention strategies.
Active principles: voglibose
Amount: 100 tablets
Maker: Sawai Pharmaceutical Co., Ltd., Osaka, Japan
Indications: decreasing reactive (post-meal) hyperglycemia
How to take
Adults should start with 0.2 mg of the active principle, 3 times a day, immediately before each meal. If the effect is insufficient, the dosage can be increased up to 0.3 mg 3 times a day, after meal. This medicine contains 0.3 mg active ingredient per tablet.
Voglibose tablets are safe to be taken with or without water. The tablet can be moistened with saliva, placed on your tongue, crushed lightly with your tongue and swallowed with saliva.
Contraindications: do not use for the following patients:
- Breastfeeding and pregnant women,
- Patients with precoma, ketosis or diabetic coma,
- Patients with an infection or other injury,
- Patients during the pre-/post-operative period.
If you notice any symptoms of hypoglycemia, such as cold and sweating, tremors in your arms or legs, or sudden fatigue, take glucose.
As hypoglycemia may cause dizziness, avoid operating dangerous machiner, driving a car or working at heights while taking this medicine.
If an allergic reaction occurs, patient needs to stop using the medicine and consult with their doctor. If patient is taking any other medication or treatment, they should consult with their doctor in advance.